

Table S1. Clinical manifestations in emergomycosis patients

Signs and symptoms	Total N (%)	HIV-Infected patients N (%)	HIV-uninfected patients N (%)	P value
Fever	46 (59.7)	38 (49.4)	8 (10.4)	0.403
Loss of weight	36 (46.8)	32 (41.6)	4 (5.2)	0.089
Cough	35 (45.5)	29 (37.7)	6 (7.8)	0.577
Dyspnoea	13 (16.9)	7 (9.1)	6 (7.8)	0.023*
Tachypnoea	8 (10.4)	7 (9.1)	1 (1.3)	>0.99
Night sweats	10 (13)	10 (13)	0	0.110
Haemoptysis	3 (3.9)	3 (3.9)	0	>0.99
Diarrhoea	14 (18.2)	12 (15.6)	2 (2.6)	0.721
Generalised lymphadenopathy	8 (10.4)	6 (7.8)	2 (2.6)	0.668
Hepatomegaly	6 (7.8)	6 (7.8)	0	0.334
Skin lesions	65 (84.4)	58 (75.3)	7 (9.1)	0.0001*

Note: The values in the table are expressed in N (number) and % (percentage). The percentages in the table were calculated using the total number of patients (N=77) as the denominator.

*The P values <0.05 were considered statistically significant.

Table S2. Opportunistic infections in emergomycosis patients

Infections	Total N (%)	HIV-Infected patients N (%)	HIV-uninfected patients N (%)	P value
<i>Opportunistic Infections</i>	29 (37.7)	26 (33.8)	3 (3.9)	0.092
<i>Fungal Infections</i>	11 (14.3)	10 (13.0)	1 (1.3)	0.442
Aspergillosis	1 (1.3)	0	1 (1.3)	0.208
Candidiasis	6 (7.8)	6 (7.8)	0	0.334
Cryptococcosis	1 (1.3)	1 (1.3)	0	>0.99
Histoplasmosis	3 (3.9)	3 (3.9)	0	>0.99
<i>Bacterial Infections</i>	15 (19.5)	13 (16.9)	2 (2.6)	0.723
<i>Mycobacterium tuberculosis</i>	4 (5.2)	4 (5.2)	0	0.574
Syphilis	1 (1.3)	1 (1.3)	0	>0.99
Non-tuberculous mycobacteria	5 (6.5)	5 (6.5)	0	0.577
Bacteremia	6 (7.8)	4 (5.2)	2 (2.6)	0.599
<i>Viral infections (other than HIV)</i>	9 (11.7)	8 (10.4)	1 (1.3)	0.675
Parvovirus	1 (1.3)	1 (1.3)	0	>0.99
Kaposi sarcoma	1 (1.3)	1 (1.3)	0	>0.99
Herpes virus	3 (3.9)	3 (3.9)	0	>0.99
Hepatitis B and C virus	3 (3.9)	3 (3.9)	0	>0.99
Cytomegalovirus	1 (1.3)	0	1 (1.3)	0.208

Note: The values in the table are expressed in N (number) and % (percentage). The percentages in the table were calculated using the total number of patients (N=77) as the denominator.

The P values <0.05 were considered statistically significant.

Table S3. Descriptions of skin lesions in emergomycosis patients

Appearances of skin lesions	Total N (%)	HIV-Infected patients N (%)	HIV-uninfected patients N (%)	P value
<i>Skin lesions^a</i>	65 (84.4)	58 (75.3)	7 (9.1)	0.0001*
Papules	32 (41.6)	28 (36.4)	4 (5.2)	0.162
Nodules	17 (22.1)	13 (16.9)	4 (5.2)	0.743
Crust	15 (19.5)	13 (16.9)	2 (2.6)	0.723
Ulceration	12 (15.6)	9 (11.7)	3 (3.9)	0.706
Plaques	11 (14.3)	10 (13)	1 (1.3)	0.442
Macules/Patches	11 (14.3)	11 (14.3)	0	0.107
Erythema	10 (13)	10 (13)	0	0.110
Verrucous	5 (6.5)	5 (6.5)	0	0.577
Dry Scales	4 (5.2)	4 (5.2)	0	0.574

Note: The values in the table are expressed in N (number) and % (percentage). The percentages in the table were calculated using the total number of patients (N=77) as the denominator.

*The P values <0.05 were considered statistically significant.

^a. The descriptions of the skin lesions were reported in n=54 patients (HIV-infected (n=48) and HIV-uninfected (n=6)).

Table S4. Radiological findings in emergomycosis patients

Radiological findings	Total N (%)	HIV-Infected patients N (%)	HIV-uninfected patients N (%)	P value
<i>Radiological findings of chest ^a</i>	<i>58 (75.3)</i>	<i>44 (57.1)</i>	<i>14 (18.2)</i>	<i>0.330</i>
Lung opacities and infiltrates	46 (59.7)	32 (41.6)	14 (18.2)	0.011*
Hilar lymphadenopathy	19 (24.7)	16 (20.8)	3 (3.9)	0.747
Lung collapse	4 (5.2)	3 (3.9)	1 (1.3)	>0.99
Pleural effusion	3 (3.9)	2 (2.6)	1 (1.3)	0.508
Lung mass	3 (3.9)	1 (1.3)	2 (2.6)	0.108
Tubercular cavities	4 (5.2)	3 (3.9)	1 (1.3)	>0.99
Pericardial effusion	2 (2.6)	2 (2.6)	0	>0.99
<i>Radiological findings of the abdomen ^a</i>	<i>21 (27.3)</i>	<i>21 (27.3)</i>	<i>0</i>	<i>0.004*</i>
Abnormal liver findings	12 (15.6)	12 (15.6)	0	0.062
Splenic Lesions	6 (7.8)	6 (7.8)	0	0.334
Abdominal lymphadenopathy	7 (9.1)	7 (9.1)	0	0.334
Abnormal Renal Findings	2 (2.6)	2 (2.6)	0	>0.99
Abdominal mass	2 (2.6)	2 (2.6)	0	>0.99

Note: The values in the table are expressed in N (number) and % (percentage). The percentages in the table were calculated using the total number of patients (N=77) as the denominator.

*The P values <0.05 were considered statistically significant.

^a. Radiological findings in the chest and abdomen were reported in n=58 and n=21 patients, respectively. Multiple findings were documented in each patient.

Table S5. Antifungal treatment in the emergomycosis patients

Treatment	Total N (%)	HIV-Infected patients N (%)	HIV-uninfected patients N (%)	P value
Anti-tubercular (ATT) and Anti-retroviral Therapy (ART)				
ATT for active disease	4 (5.2)	4 (5.2)	0	0.574
ATT empirical treatment	30 (39)	30 (39)	0	0.0001*
On ART during the presentation	30 (39)	30 (39)	0	0.0001*
ART newly initiated after diagnosis	23 (29.9)	23 (29.9)	0	0.002*
ART default before skin lesions	14 (18.2)	14 (18.2)	0	0.034*
Never on ART	3 (3.9)	3 (3.9)	0	>0.99
Antifungal Treatment ^a				
Patients on antifungal therapy	64 (83.1)	50 (64.9)	14 (18.2)	0.740
No antifungal treatment	9 (11.7)	8 (10.4)	1 (1.3)	0.740
Amphotericin B alone	8 (10.4)	7 (9.1)	1 (1.3)	>0.99
<i>Triazole alone</i>	<i>19 (24.7)</i>	<i>12 (15.6)</i>	<i>7 (9.1)</i>	<i>0.058</i>
Fluconazole alone	7 (9.1)	7 (9.1)	0	0.334
Itraconazole alone	7 (9.1)	3 (3.9)	4 (5.2)	0.031*
Posaconazole alone	1 (1.3)	0	1 (1.3)	0.208
voriconazole alone	1 (1.3)	0	1 (1.3)	0.208
Itraconazole and Fluconazole	2 (2.6)	2 (2.6)	0	>0.99
Itraconazole, Fluconazole and Posaconazole	1 (1.3)	0	1 (1.3)	0.208
<i>Amphotericin B and azole combination therapy</i>	<i>34 (44.2)</i>	<i>30 (39)</i>	<i>4 (5.2)</i>	<i>0.098</i>
Amphotericin B and Itraconazole	24 (31.2)	23 (29.9)	1 (1.3)	0.016*
Amphotericin B and Fluconazole	5 (6.5)	4 (5.2)	1 (1.3)	>0.99
Amphotericin B, Itraconazole and Fluconazole	4 (5.2)	3 (3.9)	1 (1.3)	>0.99
Amphotericin B, Voriconazole and Fluconazole	1 (1.3)	0	1 (1.3)	0.208
<i>Amphotericin B, azoles and echinocandins</i>	<i>3 (3.9)</i>	<i>1 (1.3)</i>	<i>2 (2.6)</i>	<i>0.108</i>

Amphotericin B, Posaconazole and Caspofungin	1 (1.3)	0	1 (1.3)	0.208
Amphotericin B, Voriconazole and Caspofungin	1 (1.3)	0	1 (1.3)	0.208
Amphotericin B, Itraconazole, Fluconazole and Caspofungin	1 (1.3)	1 (1.3)	0	>0.99

Note: The values in the table are expressed in N (number) and % (percentage). The percentages in the table were calculated using the total number of patients (N=77) as the denominator.

*The P values <0.05 were considered statistically significant.

^a. Antifungal treatment data was available in 73 cases. Four patients did not have treatment data [10,30].